The success of the adaptive immune system relies in part on the efficient transport of antigens by specialized antigen-presenting cells (e.g., dendritic cells (DCs) from barrier tissue such as skin (where infectious organisms first invade) to secondary lymphoid organs such as lymph nodes (LNs), where the DCs present antigen to naive and memory T cells (Randolph et al., 2005) . Although this process is critical for immune cell priming, much less is known about it, including the cytokines and adhesion molecules that are required, than about the effector phase of adaptive immunity in which T cells (and other leukocytes) migrate from the blood stream to tissue by first transiently stopping (rolling), firmly arresting, and finally crawling (diapedesis) between blood vascular endothelial cells (BVECs) to emerge on the tissue side of the blood vessel (Mackay, 1999) .
Lymphatic vessels have long been appreciated in humans. Veiled cells resembling macrophages were identified more than 40 years ago in lymphatic fluid (Smith et al., 1970) . These veiled cells were eventually recognized to be potent antigen-presenting cells called DCs; in skin, they are composed primarily of epidermal DCs called Langerhans cells (LCs) and dermal DCs.
The complex route of epidermal LCs has been of particular interest because these cells must leave the epidermis prior to entering lymphatic vessels.
Migration of LCs appears to be associated with the activation of resting LCs by inflammatory triggers such as IL-1b and tumor necrosis factor-a. The latter two cytokines not only cause LCs to strongly upregulate major histocompatibility complex class II and costimulatory molecules but also may induce the generation of lymphangiogenic cytokines such as vascular endothelial growth factor-C, which increase the number of lymphatic vessels at sites of inflammation. As LCs mature, they also downregulate expression of E-cadherin (Schwarzenberger and Udey, 1996) , which may anchor LCs to keratinocytes in the epidermis and initiate expression of matrix metalloproteinases, allowing them to pass through the basement membrane (Angeli and Randolph, 2006) . Two key membrane receptors that are upregulated with LC/DC maturation are the chemotactic receptors CC chemokine receptor-7 (CCR7) and CXC chemokine receptor-4 (CXCR4). The role of CCR7 and its two ligands (CCL19 and -21) in lymphatic trafficking is better understood because CCR7-deficient knockout mice (CCR7-KO) (Foerster et al., 1999) and paucity of LN T cells (plt) mice (Gunn et al., 1999) , which lack expression of select CCR7 chemokine ligands (CCL19/21) at the periphery and within LNs, both exhibit small peripheral LNs. This phenotype is caused by the inability of T cells to effectively migrate to LNs from peripheral tissue sites via lymphatics and from the blood. Furthermore, in both types of mice, DCs from the periphery show a marked defect in their ability to migrate to peripheral LNs. Similarly to T cells, DCs require CCR7 in order to traverse from the periphery to regional LNs. This is shown in elegant adoptive transfer experiments demonstrating that DCs from CCR7 KO mice fail to migrate to peripheral LNs after implantation in the subcutis (Martin-Fontecha et al., 2003) , in fluorescein isothiocyanate (FITC)-skin painting experiments (Foerster et al., 1999) , and in experiments in which a neutral izing antibody against the CCR7 ligand, CCL21, blocks migration of radio labeled DCs to peripheral LNs (Saeki et al., 1999) . CCR7 also appears to play a role in the mechanism by which cancer cells metastasize to the LNs (Fang and Hwang, 2009; Wiley et al., 2001) .
Central to the successful migration of DCs to the LNs is the interaction between DCs and lymphatic endothelium, which remains an area of considerable controversy. It is unclear whether DCs passively enter lymphatic vessels through spaces between adjacent lymphatic endothelial cells (LECs)-which are large enough to allow particles to pass-or whether they must squeeze themselves through closed junctions between LECs (Stoitzner et al., 2002) . Because of the small size of murine lymphatic vessels, it has been difficult to assess these interactions in vivo in mice. Most of our information comes from painting FITC on the surface of skin, which not only is taken up by LCs and other skin antigen-presenting cells but also triggers an inflammatory response that induces DC maturation. Labeled DCs can then be detected hours or days later in the draining LNs, allowing investigators to indirectly infer the action of a particular protein based on specific interventions. Using this technique, peptide antagonists of CXCR4 were shown to reduce the migration of FITC-labeled LCs from the skin to draining LNs, suggesting a role for CXCR4, without specifying where it is required in this complicated pathway (Kabashima et al., 2007a) .
In this issue, Torzicky et al. examine the role of adhesion molecules in the RT of monocyte-derived DCs through LEC monolayers. The investigators first noted that CD31 and CD99 were expressed by LECs and human LECs from skin explants. In contrast to BVECs, on which CD31 and CD99 both localize to cell junctions (Mamdouh, 2009), Torzicky and colleagues observed that CD31 in human skin was enhanced on LEC cell junctions whereas CD99 and podoplanin were found on the luminal side of the lymphatic vessel from skin. CD31 (also known as PECAM-1) is an adhesion molecule that forms homo-oligomers between cells, possibly triggering an increase in the strength of adhesion of integrins. It is highly expressed on many leukocytes and BVECs, but somewhat more weakly on LECs. CD99 is a heavily glycosylated transmembrane protein that is expressed by most hematopoietic cells as well as endothelial cells. Blocking antibodies to CD99 appears to "freeze" monocytes midway in the junction between BVECs in transmigration assays, whereas CD31 blocking antibodies seem to prevent monocytes from even entering the junction (Schenkel et al., 2002) . Thus, for migration from the luminal side of the blood vessel, the role of CD31 seems to be spatially proximal to the role of CD99.
Although CD31 and CD99 have been shown to play roles in leukocyte diapedesis in BVECs, their roles in DC/ LEC trafficking are unknown. To provide a reductionist model system by which to study the adhesion molecules required for RT, Torzicky et al. (2012) cultured telomerase-expressing human LECs on Transwell filter membranes such that the basolateral surface of the monolayer was on the bottom, but then flipped the Transwell filters over, added cultured mDCs to the top chamber, and placed chemoattractants such as CXCL12 in the bottom chamber to generate a chemokine gradient. (LCs) are activated by pathogens and/or skin inflammatory cytokines. After downregulating E-cadherin and upregulating CCR7, CXCR4, and metalloproteinases, LCs enter the dermis. It is still not clear whether a gradient of CCR7 ligands (CCL21 or CCL19) or CXCR4 ligands (CXCL12) attracts LCs toward lymphatic vessels. Both ligands can be produced by lymphatic endothelial cells (LECs). Homo-oligomeric interaction between first CD31 at the intercellular junction between LECs and then CD99 on the luminal surface of lymphatic vessels may be requisite adherence events that eventually lead to LCs' passage into the lumen of the lymphatic vessel, where lymphatic flow may propel these cells to the regional draining lymph node. Both CD31 and CD99 are expressed by DCs and LECs. MMPs, matrix metalloproteinases; TNF, tumor necrosis factor.
In this modified Transwell assay, CXCL12 had a powerful effect in attracting monocyte-derived DCs through the LEC monolayer barrier. CXCL12 and CCL21 were similar in their abilities to induce migration. Treatment of either the LECs or the monocyte-derived DCs with anti-CD31 or -99 monoclonal antibodies (mAbs) resulted in a substantial inhibition of RT migration, suggesting that these molecules play a key role in this interaction. Treating either cell with antibody had an inhibitory effect, substantiating the role of homo-oligomerization of these molecules in their mechanism of adhesion. Blocking with a combination of both mAbs did not yield better inhibition, and one might infer that these antibodies target discrete steps in transmigration. Based on the distribution of CD99 (on the luminal surface) and CD31 (between LEC junctions) observed by these investigators, one might hypothesize that the action of CD31 is proximal to that of CD99 during the RT migration of DCs, analogous to their proposed roles in BVEC trafficking (see above). Torzicky et al. (2012) also demonstrated that in vitro LECs are capable of producing CXCL12, which can be modestly enhanced by treating LECs with inflammatory cytokines. When staining human skin samples, they noted that CXCL12 was located in BVECs and LECs but could not be detected in fibroblasts, suggesting that the LECs themselves may be important sources of CXCL12 for transmigration.
Because the monolayer LEC RT model cannot simulate the complex environment of skin, Torzicky et al. examined whether CXCL12, CD99, and CD31 have a role in DC emigration, using a skin explant model. They quantitated the percentage of human leukocyte antigen-DR + cells found in the dermis (as a percentage of the total DCs in both epidermis and dermis) as a measure of DC migration into the dermis. When they added CXCL12 to the culture medium, they observed a substantially higher fraction of DCs in the dermis, and this was partially inhibited by mAbs to CD31 and CD99. The effect of the anti-CD31 and -CD99 mAbs is somewhat puzzling because they would not be expected to block DC migration into the dermis. Although measuring the ability of DCs to enter lymphatics would have been very helpful, this is technically challenging in frozen sections, and a quantitative measure was not shown by the authors. In any event, the inhibitory effect was modest and may have occurred for other reasons. It is clear, however, that CXCL12 is a powerful stimulant for DCs to migrate from the epidermis to the dermis. Others have shown that CXCL12 can drive DC migration from skin explants into culture medium but that CCL21 has a more profound effect (Saeki et al., 1999) . As noted by others (Randolph et al., 2005) , skin explant models have limitations, including poor viability of the cultured tissue. Given that Kabashima et al. (2007b) have reported that CXCR4 activation can increase DC survival, it is also possible that the addition of CXCL12 to the culture medium increased DC viability. In summary, Torzicky et al. (2012) have shown that CD31, CD99, and CXCR4 play notable roles in RT in vitro and ex vivo. Their localization studies of CD31 and CD99 provide valuable insight into the possibility that adhesion occurs in a defined sequence during the passage of DCs through LECs. Although not entirely conclusive, their ex vivo studies help to answer the question of whether DC entry into lymphatics is a passive or active process, suggesting that there are active mechanisms at hand. In vivo studies would be needed to yield definitive results. Based on their new data, however, one can propose a model of DC interaction with LECs that involves these molecules and, possibly, CCR7 ligands as well (Figure 1) . Although purely speculative at this point, one wonders whether CD99 and CD31 on the surface of LCs (DCs) can be redistributed to adhere to these molecules on LECs in such a way that they act as anchoring points for further migration.
Finally, although they demonstrate a role for CXCR4, Torzicky et al. have not directly addressed the relative importance of CCR7 compared with CXCR4 in DC migration. The use of neutralizing anti-CCL21/CCL19 antibodies in this skin explant model would have helped to address this important, yet unanswered, question.
Moreover, more precise localization of the chemokines involved might also explain their roles in DC migration. There is still much to be answered, but these studies provide a new perspective on how DCs make their fascinating journey from skin to LN.
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Because melanocytes constitute a minority population in the epidermis, efficient transfer of melanosomes (the organelle responsible for melanin synthesis) to keratinocytes is critical in providing photoprotection to the skin. The melanocyte has multiple dendrites, which contact basal as well as suprabasal keratinocytes. The biologic importance of melanosome transfer is easily appreciated after exposure of skin, or melanocytekeratinocyte cocultures, to UVR, which induces increased synthesis of melanin, enhanced dendrite formation by melanocytes, and melanosome transfer. Disordered melanosome transfer due to defects in rab27a and myosin Va are seen in Griscelli syndrome, a rare autosomal recessive disorder characterized by partial albinism and immune deficiency (Barral et al., 2002; Hume et al., 2002; Novak et al., 2002) . Understanding the nature of this process has clinical implications for photocarcinogenesis and disorders of pigmentation, including melasma and postinflammatory pigmentary disorders. Historical models of melanosome transfer were based primarily on static electron micrographs of cocultures and low-resolution video microscopy. Despite these technical limitations, investigators were able to propose several mechanisms, including phagocytosis of dendrite tips by keratinocytes, individual melanosome "exocytosis," and an "inoculation" model in which dendrite tips were inserted directly into the keratinocyte membrane (Okazaki et al., 1976; Yamamoto and Bhawan, 1994) . In 2002, using high-resolution time-lapse microscopy and electron micrographs, we identified a novel mechanism of melanosome transfer through thin actin-based structures called "filopodia" and showed that the small GTP-binding protein Cdc42 stimulates melanosome transfer (Scott et al., 2002) . Transport of melanosomes along microtubules has been shown to be driven by the motor protein kinesin (Hara et al., 2000) , and a critical receptor for melanosome uptake, PAR-2, has been identified on keratinocytes. The PAR-2 receptor is upregulated by UV irradiation, and it mediates the engulfment of melanosomes in a mechanism similar to that of traditional phagocytosis-mediated processes (Seiberg, 2001; Sharlow et al., 2000) .
Shedding microvesicles in melanosome transfer
In their study reported in this issue, Ando et al. used scanning electron microscopy and immunofluorescence microscopy of melanocytes in which the plasma membrane was stained to demonstrate the presence of "pigment globules" adhering to dendrites. Scanning electron microscopy showed that multiple filopodia were assoc iated with the pigment globules. The pigment globules consisted of multiple melanosomes tightly packaged into a single membrane structure 2-7 μm in diameter. These structures resembled shedding microvesicles, which are single-membrane vesicles that are a vehicle for transport of a variety of 
